Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis

Exclusion Criteria

• •1. Women who are known to be pregnant, who have given birth within the past 90 days, or who are breastfeeding.
• •2. Any condition or laboratory findings which in the opinion of the Investigator makes the patient unsuitable for inclusion
• •3. Enrolled in either another investigational drug study or in another investigational study of an approved drug within 30 days prior to Visit 1 of the current study.
• •4. Known allergies or intolerance to aspirin and/or thienopyridines (clopidogrel or ticlopidine).
• •5. Significant active neuropsychiatric disease, alcohol abuse or drug abuse, in the investigator's opinion.
• •6. UCR or Accumetrics employees or investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
• •7. Subjects with unstable coronary artery disease, defined as new, increased, or rest angina at screening.
• •8. Subjects with significant hypertension (systolic blood pressure \> 180 mm Hg or diastolic blood pressure \>110 mmHg) at the time of screening.
• •9. Any known contraindication to treatment with an anticoagulant or antiplatelet agent.
• •10. Prior history or presence of significant bleeding disorders (for example,hematemesis, melena, severe or recurrent epistaxis, hemoptysis, hematuria, or intraocular bleeding)
• •11. Prior history or clinical suspicion of cerebral vascular malformations
• •12. Prior history of abnormal bleeding tendency (i.e. prolonged bleeding on dental extraction, tonsillectomy, or previous surgical procedure).
• •13. Personal or family history of coagulation or bleeding disorders.
• •14. Thrombocytopenia (platelet count \< 100,000/mm3) or thrombocytosis (platelet count \> 500,000/mm3).
• •15. History of major surgery, severe trauma, organ biopsy within 3 months prior to enrollment.
• •16. Any planned surgical procedure within 20 days following inclusion.
• •17. The use (or planned use) of other antiplatelet agents (besides aspirin and clopidogrel), anticoagulant or fibrinolytic agents.